文献速递乳腺癌

高免赔额保险参保后乳腺癌诊断与治疗延迟

Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment.
PubMed 文献 · J Clin Oncol · 2018-02-28

结果显示HDHP参保后诊断性乳腺影像、活检、早期乳腺癌诊断和化疗启动均出现延迟。

要点

  • HDHP参保后诊断性乳腺影像延迟(aHR 0.95)。
  • 乳腺活检延迟(aHR 0.92),早期乳腺癌诊断延迟(aHR 0.83)。
  • 化疗启动延迟(aHR 0.79)。

核心结论

  • 转为HDHP的女性在诊断性乳腺影像、乳腺活检、早期乳腺癌诊断和化疗启动方面均出现延迟。

研究设计与样本

  • 采用对照前后设计结合生存分析,纳入273,499名25-64岁无乳腺癌证据的女性,连续参保低免赔额(0-500美元)计划1年后,雇主强制转为HDHP(免赔额至少1,000美元)并随访至多4年。
  • 研究纳入为滚动进行,随访期间为2003年至2012年。

主要发现

  • 与对照组相比,HDHP成员诊断性影像接受延迟(aHR 0.95;95% CI 0.94-0.96)。
  • HDHP成员乳腺活检延迟(aHR 0.92;95% CI 0.89-0.95)。
  • HDHP成员早期乳腺癌诊断延迟(aHR 0.83;95% CI 0.78-0.90)。
  • HDHP成员化疗启动延迟(aHR 0.79;95% CI 0.72-0.86)。

临床怎么用

  • 肿瘤内科医生应关注高免赔额保险患者的乳腺癌诊疗延迟风险。
  • 政策制定者可考虑选择性降低关键乳腺癌服务的自付费用。

局限性

  • 需进一步研究确定此类延迟是否导致不良健康结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose High-deductible health plans (HDHPs) require substantial out-of-pocket spending and might delay crucial health services. Breast cancer treatment delays of as little as 2 months are associated with adverse outcomes. Methods We used a controlled prepost design with survival analysis to assess timing of breast cancer care events among 273,499 women age 25 to 64 years without evidence of breast cancer before inclusion. Women were included if continuously enrolled for 1 year in a low-deductible ($0 to $500) plan followed by up to 4 years in a HDHP (at least $1,000 deductible) after an employer-mandated switch. Study inclusion was on a rolling basis, and members were followed between 2003 and 2012. The comparison group comprised 2.4 million contemporaneously matched women whose employers offered only low-deductible plans. Measures were times to first diagnostic breast imaging (diagnostic mammogram, breast ultrasound, or breast magnetic resonance imaging), breast biopsy, incident early-stage breast cancer diagnosis, and breast cancer chemotherapy. Outcomes were analyzed by using Cox models and adjusted for age-group, morbidity score, poverty level, US region, index date, and employer size. Results After the index date, HDHP members experienced delays in receipt of diagnostic imaging (adjusted hazard ratio [aHR], 0.95; 95% CI, 0.94 to 0.96), biopsy (aHR, 0.92; 95% CI, 0.89 to 0.95), early-stage breast cancer diagnosis (aHR, 0.83; 0.78 to 0.90), and chemotherapy initiation (aHR, 0.79; 95% CI, 0.72 to 0.86) compared with the control group. Conclusion Women switched to HDHPs experienced delays in diagnostic breast imaging, breast biopsy, early-stage breast cancer diagnosis, and chemotherapy initiation. Additional research should determine whether such delays cause adverse health outcomes, and policymakers should consider selectively reducing out-of-pocket costs for key breast cancer services.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wharam JF, Zhang F, Lu CY, et al. Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment. J Clin Oncol. 2018. PMID: 29489428. doi:10.1200/JCO.2017.75.2501

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。